Tandem Diabetes Care, Inc.

Most Recent

  • uploads///diabetes _
    Company & Industry Overviews

    Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump

    Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.

    By Sarah Collins
  • uploads///animas exit from insulin pump business
    Company & Industry Overviews

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.

    By Sarah Collins
  • uploads///diabetes _
    Company & Industry Overviews

    Why Tandem Diabetes Care Stock Is Crashing Today

    The rating downgrade from Baird on September 14 triggered the downward trend in Tandem stock.

    By Sarah Collins
  • uploads///office _
    Company & Industry Overviews

    How Tandem Diabetes Care Is Advancing Its Product Pipeline

    Tandem Diabetes Care (TNDM) plans to file an application seeking FDA approval for use of its Control-IQ technology in t: slim X2 insulin pumps for patients aged 14 and above.

    By Margaret Patrick
  • uploads///diabetes _
    Company & Industry Overviews

    Tandem or Insulet: Who Is Reporting Faster Pump Uptake?

    In the first quarter, Tandem Diabetes Care (TNDM) shipped 14,700 insulin pumps, a YoY rise of 232%.

    By Margaret Patrick
  • uploads///arrows _
    Company & Industry Overviews

    Tandem Diabetes and Insulet: Comparing Revenue Growth

    In its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue guidance.

    By Margaret Patrick
  • uploads///diabetes _
    Company & Industry Overviews

    How Analysts Rate Tandem Diabetes Care and Insulet

    Until the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic and Johnson & Johnson.

    By Margaret Patrick
  • uploads///equipment _
    Company & Industry Overviews

    Tandem Diabetes Care Stock Has Skyrocketed in 2018

    On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.

    By Daniel Collins
  • uploads///TNDM
    Company & Industry Overviews

    Why Wall Street Is Still Bullish on Tandem Stock

    This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.

    By Kenneth Smith
  • uploads///diabetes _
    Company & Industry Overviews

    Why Tandem Should Be on Your Stock Radar

    Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.

    By Kenneth Smith
  • uploads///Diabetes
    Company & Industry Overviews

    A Look into Johnson & Johnson’s Diabetes Care Business

    In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.

    By Daniel Collins
  • uploads///TNDM
    Company & Industry Overviews

    What to Expect from Tandem’s Product Pipeline

    T:sport is Tandem’s next-generation hardware platform, which is expected to reduce the size of the t:slim pump by 50%.

    By Kenneth Smith
  • uploads///DIABETES
    Company & Industry Overviews

    JNJ Exits Insulin Pump Business amid Stiff Competition

    On October 5, 2017, & Johnson’s (JNJ) diabetes care company, Animas, announced its plans to exit the insulin pump business.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.